[ XXXX in advanced age].

@entity1 @entity440 @entity0
The incidence of @entity0 increases with advancing age. In view of the progressive aging of the population, this problem will tend to become more and more frequent. At present, @entity1 of advanced age are often "undertreated" owing to the mistaken prejudice that older @entity1 are unable to withstand standard multimodal therapy for this disease. In fact, there is no scientific evidence to that effect. Treatment choices should therefore be largely comparable to those adopted in younger @entity1 . Even chemotherapy, which encounters the strongest resistance, by @entity1 but also by doctors, should be administered when indicated. A number of studies have demonstrated that the toxic and side effects observed in elderly @entity1 are comparable to those observed in younger age groups. In practice, particular attention needs to be paid when administering cytostatic treatment to @entity1 over 80 years of age. Very conservative treatment ( @entity440 plus radiotherapy) may be reserved only to particularly frail elderly @entity1 . In conclusion, the therapeutic choice should depend more on assessment of the biological age, life expectancy and @entity1 's expectations than on the anagraphic age.
